• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

奥密克戎变异株流行期间德国针对重症 COVID-19 的疫苗效力：COViK 研究结果。

Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study.

机构信息

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany.

Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.

出版信息

Infection. 2023 Aug;51(4):1093-1102. doi: 10.1007/s15010-023-02012-z. Epub 2023 Mar 13.

DOI:10.1007/s15010-023-02012-z
PMID:36913112
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10009838/
Abstract

PURPOSE

COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave.

METHODS

We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates.

RESULTS

21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12-78%), 81.5% (95% CI: 68-90%) and 95.6% (95%CI: 88-99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses.

CONCLUSION

Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.

摘要

目的

COViK 是一项在德国进行的前瞻性医院多中心病例对照研究，旨在评估 COVID-19 疫苗对严重疾病的有效性。在这里，我们报告了在奥密克戎（Omicron）浪潮期间 COVID-19 疫苗对住院和重症监护治疗的有效性（VE）。

方法

我们分析了 2021 年 12 月 1 日至 2022 年 9 月 5 日期间在 13 家医院招募的 276 例 COVID-19 病例和 494 例对照患者的数据。我们计算了粗 VE 和混杂因素调整后的 VE 估计值。

结果

21%（57/276）的病例未接种疫苗，而 5%（26/494）的对照未接种疫苗（p<0.001）。混杂因素调整后的 COVID-19 导致住院的 VE 分别为 55.4%（95%CI：12-78%）、81.5%（95%CI：68-90%）和 95.6%（95%CI：88-99%），分别在接种两、三、四剂疫苗后。接种三剂疫苗后一年，预防 COVID-19 住院的 VE 仍然稳定。

结论

三剂疫苗对预防严重疾病仍然高度有效，并且这种保护作用是持续的；第四剂进一步增加了保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/34c29bddfea6/15010_2023_2012_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/c1a8f14b983b/15010_2023_2012_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/bdf3f7867956/15010_2023_2012_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/c0ec2e6f875e/15010_2023_2012_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/7147a5ae24c3/15010_2023_2012_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/34c29bddfea6/15010_2023_2012_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/c1a8f14b983b/15010_2023_2012_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/bdf3f7867956/15010_2023_2012_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/c0ec2e6f875e/15010_2023_2012_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/7147a5ae24c3/15010_2023_2012_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b4/10352147/34c29bddfea6/15010_2023_2012_Fig5_HTML.jpg

相似文献

1
Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study.奥密克戎变异株流行期间德国针对重症 COVID-19 的疫苗效力：COViK 研究结果。
Infection. 2023 Aug;51(4):1093-1102. doi: 10.1007/s15010-023-02012-z. Epub 2023 Mar 13.
2
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性：一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
3
High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron.在奥密克戎出现前后，芬兰老年人对严重 COVID-19 的疫苗有效性很高。
BMC Infect Dis. 2022 Nov 5;22(1):816. doi: 10.1186/s12879-022-07814-4.
4
Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.法国 50 岁及以上成年人中 COVID-19 mRNA 疫苗对 Delta 和奥密克戎 BA.1 症状性和严重 COVID-19 结局的有效性和保护持续时间。
Vaccine. 2023 Mar 24;41(13):2280-2288. doi: 10.1016/j.vaccine.2023.02.062. Epub 2023 Feb 27.
5
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).新型冠状病毒病 19（COVID-19）疫苗对日本德尔塔主导和奥密克戎主导期间有症状的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的有效性：一项多中心前瞻性病例对照研究（与 SARS-CoV-2 感染相关的因素和 COVID-19 疫苗的有效性研究）。
Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635.
6
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.奥密克戎 BA.4 和 BA.5 亚谱系流行期间，根据疫苗接种状态估计 COVID-19 mRNA 疫苗有效性和 COVID-19 疾病及严重程度。
JAMA Netw Open. 2023 Mar 1;6(3):e232598. doi: 10.1001/jamanetworkopen.2023.2598.
7
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间，mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
8
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.美国 Delta 和奥密克戎变异株流行期间估计 COVID-19 mRNA 疫苗在孕妇中对有医疗需要的 COVID-19 的有效性。
JAMA Netw Open. 2022 Sep 1;5(9):e2233273. doi: 10.1001/jamanetworkopen.2022.33273.
9
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
10
Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study.中国 SARS-CoV-2 奥密克戎 BA.2.2 爆发期间 COVID-19 疫苗加强针的有效性：一项病例对照研究。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2194189. doi: 10.1080/21645515.2023.2194189. Epub 2023 Mar 30.

引用本文的文献

1
Longitudinal Immunoprofiling of the CD8 T-Cell Response in SARS-CoV-2 mRNA Vaccinees and COVID-19 Patients.新冠病毒mRNA疫苗接种者和新冠肺炎患者中CD8 T细胞反应的纵向免疫分析
Vaccines (Basel). 2025 May 22;13(6):551. doi: 10.3390/vaccines13060551.
2
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.2019冠状病毒病疫苗对成人严重急性呼吸综合征冠状病毒2感染及严重后果的有效性：截至2024年1月22日发表的欧洲研究的系统评价和荟萃分析
Eur Respir Rev. 2025 Feb 19;34(175). doi: 10.1183/16000617.0222-2024. Print 2025 Jan.
3

本文引用的文献

1
Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.疫苗预防 COVID-19 住院的有效性：基于多中心医院的病例对照研究，德国，2021 年 6 月至 2022 年 1 月。
Vaccine. 2023 Jan 9;41(2):290-293. doi: 10.1016/j.vaccine.2022.11.065. Epub 2022 Dec 2.
2
Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals.89 家德国医院中 B.1.1.529（奥密克戎）优势期与 B.1.617.2（德尔塔）相比 COVID-19 患者的特征和结局。
BMC Infect Dis. 2022 Oct 27;22(1):802. doi: 10.1186/s12879-022-07781-w.
3
Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis.
意大利两家转诊医院中使用瑞德西韦治疗新冠肺炎住院患者的真实生活经验：一项倾向评分匹配分析
Sci Rep. 2024 Apr 23;14(1):9303. doi: 10.1038/s41598-024-59957-w.
4
Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany's experience during the COVID-19 pandemic, July 2021 to March 2023.应用常规监测数据估算 COVID-19 疫苗有效性的筛选方法：德国在 2021 年 7 月至 2023 年 3 月期间的 COVID-19 大流行期间的经验。
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2023.29.8.2300329.
5
A bead-based multiplex assay covering all coronaviruses pathogenic for humans for sensitive and specific surveillance of SARS-CoV-2 humoral immunity.一种基于珠粒的多重分析检测方法，可检测所有对人类致病的冠状病毒，用于 SARS-CoV-2 体液免疫的灵敏和特异性监测。
Sci Rep. 2023 Dec 9;13(1):21846. doi: 10.1038/s41598-023-48581-9.
6
Long-Term Trends in the Protection Against Severe Courses of COVID-19 by Vaccination.接种疫苗预防COVID-19重症病程的长期趋势
Dtsch Arztebl Int. 2023 Dec 27;120(51-52):873-878. doi: 10.3238/arztebl.m2023.0230.
7
Vaccine-Induced or Hybrid Immunity and COVID-19-Associated Mortality During the Omicron Wave.奥密克戎变异株流行期间疫苗诱导或混合免疫与 COVID-19 相关死亡率。
Dtsch Arztebl Int. 2023 Mar 31;120(13):213-220. doi: 10.3238/arztebl.m2023.0051.
Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
面对奥密克戎变异株——疫苗对轻症和重症 COVID-19 的保护效果如何？一项实时系统评价的第三次中期分析。
Front Immunol. 2022 Aug 24;13:940562. doi: 10.3389/fimmu.2022.940562. eCollection 2022.
4
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis.新冠疫苗对现实世界中关注的 SARS-CoV-2 变异株的有效性：文献综述和荟萃分析。
Emerg Microbes Infect. 2022 Dec;11(1):2383-2392. doi: 10.1080/22221751.2022.2122582.
5
Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis.新型严重急性呼吸综合征冠状病毒 2 株引起的 COVID-19 的潜伏期：系统评价和荟萃分析。
JAMA Netw Open. 2022 Aug 1;5(8):e2228008. doi: 10.1001/jamanetworkopen.2022.28008.
6
Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract.SARS-CoV-2 奥密克戎 BA.2 变异株在人体上下呼吸道体外培养物中的复制。
EBioMedicine. 2022 Sep;83:104232. doi: 10.1016/j.ebiom.2022.104232. Epub 2022 Aug 18.
7
Clinical characteristics of the severe acute respiratory syndrome coronavirus 2 omicron variant compared with the delta variant: a retrospective case-control study of 318 outpatients from a single sight institute in Japan.与德尔塔变异株相比，严重急性呼吸综合征冠状病毒 2 奥密克戎变异株的临床特征：来自日本单一眼科机构的 318 例门诊患者的回顾性病例对照研究。
PeerJ. 2022 Aug 2;10:e13762. doi: 10.7717/peerj.13762. eCollection 2022.
8
Response to Beran et al.对贝兰等人的回应
J Infect Dis. 2022 Sep 13;226(5):944-945. doi: 10.1093/infdis/jiac259.
9
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.既往感染和疫苗接种对奥密克戎感染症状的影响。
N Engl J Med. 2022 Jul 7;387(1):21-34. doi: 10.1056/NEJMoa2203965. Epub 2022 Jun 15.
10
Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.严重急性呼吸综合征冠状病毒2型奥密克戎变种对治疗性单克隆抗体的敏感性：系统评价和荟萃分析。
Microbiol Spectr. 2022 Aug 31;10(4):e0092622. doi: 10.1128/spectrum.00926-22. Epub 2022 Jun 14.